Endra Life Sciences Inc.
NDRAEndra Life Sciences Inc. in brief
Endra Life Sciences Inc. is a listed company in the Diagnostics and Research industry, based in Ann Arbor, Michigan, USA. Its market value was $7 M on 30 October 2026, which makes it the 26,385th largest listed company in the world and the 4,347th largest in the USA on this site. It employs about 11 people and Alexander Y. Tokman is its chief executive. Its shares trade under the symbol NDRA (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Endra Life Sciences Inc.
We were incorporated as a Delaware corporation in 2007. We are developing a next-generation enhanced ultrasound technology platform—Thermo- Acoustic Enhanced Ultrasound, or TAEUS®.
We have periodically evaluated and refined our vision, purpose, and go-to-market strategy with respect to TAEUS in response to evolving market conditions and development priorities.
We plan to offer a multi-year, subscription-based business model with recurring revenue, while continuing to support traditional capital equipment sales with associated service and upgrade offerings.
From the company's annual report filed with the US SEC: read the report
Endra Life Sciences Inc. timeline
- 2016
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- ✎Renamed ENDRA Life Sciences Inc.Formerly Endra Inc..
- 2017
- 🔔Initial public offering on NasdaqFinal prospectus filed with the SEC on 10 May 2017; shares registered for exchange trading on 4 May 2017.
Events of Endra Life Sciences Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #4,519 (Jan 2020) · #4,335 (Jan 2021) · #5,180 (Jan 2022) · #5,354 (Dec 2022) · #5,458 (Jul 2023) · #4,478 (Jan 2024) · #2,455 (Mar 2026) · #4,099 (Aug 2026) · #4,350 (Oct 2026)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- —
- Price / book
- 3.3×
- Free cash flow yield
- -70.2%
- Net margin
- —
- Operating margin
- —
- Return on equity
- -311.1%
- Liabilities / assets
- 41.3%
- Net debt
- $-3M
- Revenue growth
- -97.1%
- R&D / revenue
- 47200.0%
- Profit per employee
- $-639 K
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | — | — | $-6M | $-7M | — |
| Dec 2024 | — | — | $-11M | $-12M | — |
| Dec 2023 | — | — | $-11M | $-10M | — |
| Dec 2022 | — | — | $-13M | $-13M | — |
| Dec 2021 | — | — | $-12M | $-11M | — |
| Dec 2020 | — | — | $-12M | $-12M | — |
| Dec 2019 | — | — | $-11M | $-13M | — |
| Dec 2018 | $0M | — | $-9M | $-10M | -98000.0% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-5M | $0M | $-5M | $-8.93 | — |
| Dec 2024 | $-7M | $0M | $-7M | $-56.94 | — |
| Dec 2023 | $-10M | $0M | $-10M | $-2766.85 | — |
| Dec 2022 | $-13M | $0M | $-13M | — | — |
| Dec 2021 | $-11M | $0M | $-11M | — | — |
| Dec 2020 | $-11M | $0M | $-11M | $-0.63 | — |
| Dec 2019 | $-9M | $0M | $-9M | $-2.34 | — |
| Dec 2018 | $-8M | $0M | $-8M | $-2.17 | — |
Quarterly results
Latest quarter to Jun 2026: revenue —, net income $0M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Jun 2026.
SEC filings
- Oct 1, 20268-KCurrent reportMaterial agreement
- Aug 17, 20268-KCurrent reportResults of operations
- Aug 14, 202610-QQuarterly report · period to Jun 2026
- Jul 9, 20268-KCurrent reportOther events
- Jun 26, 20268-KCurrent reportMaterial agreement · Change in control · Regulation FD disclosure · Other events
- Jun 25, 20268-KCurrent reportRegulation FD disclosure
- May 28, 20268-KCurrent reportMaterial agreement · Unregistered share sale · Other events
- May 15, 202610-QQuarterly report · period to Mar 2026
- Apr 21, 20268-KCurrent reportListing notice
- Mar 31, 202610-KAnnual report · period to Dec 2025
- Mar 31, 20268-KCurrent reportResults of operations
- Mar 25, 20268-KCurrent reportRestructuring costs · Regulation FD disclosure
Official filings of Endra Life Sciences Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- —
- Operating income
- $-6 M
- Net income
- $-7 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $4 M
- Total liabilities
- $2 M
- Total equity
- $2 M
As of December-2025
Top 12 institutional investors in Endra Life Sciences Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Altium Capital Management LLC | 54,528 | -4,744 (-8.00%) | 3.64% | $0 M | Nov 4, 2026 |
| 2 | Citizens Financial Group Inc/ri | 28,400 | 0 (0.00%) | 1.89% | $0 M | Oct 23, 2026 |
| 3 | Citadel Advisors LLC | 20,745 | -9,179 (-30.67%) | 1.38% | $0 M | Nov 16, 2026 |
| 4 | Renaissance Technologies LLC | 18,764 | New | 1.25% | $0 M | Nov 12, 2026 |
| 5 | Geode Capital Management, LLC | 14,910 | 0 (0.00%) | 0.99% | $0 M | Nov 6, 2026 |
| 6 | Vanguard Fiduciary Trust Co | 10,121 | 0 (0.00%) | 0.67% | $0 M | Nov 13, 2026 |
| 7 | Vanguard Capital Management LLC | 7,339 | 0 (0.00%) | 0.49% | $0 M | Nov 13, 2026 |
| 8 | UBS Group AG | 5,942 | +5,874 (+8638.24%) | 0.40% | $0 M | Nov 10, 2026 |
| 9 | Morgan Stanley | 3,546 | 0 (0.00%) | 0.24% | $0 M | Nov 13, 2026 |
| 10 | Citigroup Inc | 1,078 | New | 0.07% | $0 M | Nov 4, 2026 |
| 11 | Tower Research Capital LLC (TRC) | 883 | +825 (+1422.41%) | 0.06% | $0 M | Nov 16, 2026 |
| 12 | Northwestern Mutual Wealth Management Co | 19 | 0 (0.00%) | 0.00% | $0 M | Nov 13, 2026 |
Mutual funds holding Endra Life Sciences Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 14,580 | $0 M | 0.97% | <0.01% | +138% | May 31, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 7,339 | $0 M | 0.49% | <0.01% | +161% | Jun 30, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 1,597 | $0 M | 0.11% | <0.01% | no change | May 31, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jun 30, 2026. The 3 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Endra Life Sciences Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Alexander Y. TokmanChief Executive Officer, Director | Grant or award | +26,921 | — | — | 101,926 | Form 4 |
| filed | Richard JacrouxChief Financial Officer | Grant or award | +13,461 | — | — | 33,461 | Form 4 |
| filed | Michael HarshDirector | Grant or award | +60,324 | — | — | 65,710 | Form 4 |
| filed | Anthony DigiandomenicoDirector | Grant or award | +60,324 | — | — | 136,589 | Form 4 |
| filed | Lou BaseneseDirector | Grant or award | +60,324 | — | — | 65,709 | Form 4 |
| filed | Alexander Y. TokmanChief Executive Officer, Director | Grant or award | +75,000 | — | — | 75,005 | Form 4 |
| filed | Richard JacrouxChief Financial Officer | Grant or award | +20,000 | — | — | 20,000 | Form 4 |
| filed | Anthony DigiandomenicoDirector | Grant or award | +70,822 | $7.060 | $500 K | 76,265 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Endra Life Sciences Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Trading halts
- 2026-11-17 17:21 UTC, code LUDP, resumed 17:26 UTC
- 2026-06-25 13:57 UTC, code LUDP, resumed 14:02 UTC
- 2026-06-25 13:47 UTC, code LUDP, resumed 13:52 UTC
- 2026-06-25 13:36 UTC, code LUDP, resumed 13:46 UTC
- 2026-06-25 13:30 UTC, code LUDP, resumed 13:35 UTC
Fails to deliver
- : 2 shares at $4.94
- : 1,941 shares at $6.46
- : 2,173 shares at $5.61
- : 2,761 shares at $5.54
- : 2,780 shares at $5.49
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Endra Life Sciences Inc. scorecard#
Passes 3 of the 12 checks that could be worked out: strongest in valuation (1 of 4), weakest in profitability (0 of 3). Fiscal year 2025; market cap of Oct 30, 2026.
Valuation1 of 4
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✓Price to book below its peers' median3.3×Price to book 3.3× against Diagnostics and Research's median of 3.7×.
- –Price to sales below its peers' medianNo Price to sales on file.
- ✗Free cash flow yield above 5%-70.2%Free cash flow is -70.2% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth1 of 2
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-8.93 vs -56.94Diluted EPS -8.93 in fiscal 2025 against -56.94 the year before (report's currency).
- ✓Net income higher than five years earlier-$7 M-$7 M in fiscal 2025 against -$12 M in 2020.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 3
- ✗Profitable in the newest year-$7 MNet income -$7 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- –Operating margin above its peers' medianNo operating margin on file.
- ✗Return on equity above 15%-291.7%-291.7% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health1 of 2
- ✓Short-term assets cover short-term liabilities1.3×Current ratio 1.29 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year289.6%Diluted shares up 289.6% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Diagnostics and Research, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Endra Life Sciences Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | — | — | — | — | — | 0—— | 0−100%— | 0.0−98.2%100% | 0.4−31.8%100% | 0.5—100% | |
| Cost of revenue | — | — | — | — | — | 0—— | 0—— | 0−100%0.0% | 0.2—49.1% | — | |
| Gross profit | — | — | — | — | — | 0—— | 0−100%— | 0.0−96.5%100% | 0.2−36.1%50.9% | 0.3—54.3% | |
| Research and development | 1.8−42.0%— | 3.2−36.2%— | 5.0−23.7%— | 6.6+19.5%— | 5.5−7.4%— | 5.9−10.0%— | 6.6+39.2%— | 4.7+145%76490% | 1.9+290%549% | 0.5—96.1% | |
| Selling and marketing | 0.2−66.8%— | 0.6−30.4%— | 0.8−42.6%— | 1.4+32.9%— | 1.1+84.8%— | 0.6+41.1%— | 0.4+57.0%— | 0.3+114%4254% | 0.1+259%34.9% | 0.0—6.6% | |
| General and administrative | 3.7−47.2%— | 7.1+50.2%— | 4.7−9.2%— | 5.2+4.7%— | 4.9−1.2%— | 5.0+29.7%— | 3.9+2.8%— | 3.8+36.4%60780% | 2.8+78.4%782% | 1.5—299% | |
| Operating expenses | 5.8−46.7%— | 11+2.8%— | 11−20.0%— | 13+14.4%— | 11−0.0%— | 12+6.1%— | 11+20.1%— | 9.0+87.8%146180% | 4.8+132%1366% | 2.1—402% | |
| Operating income | −5.8—— | −11—— | −11—— | −13—— | −11—— | −12—— | −11—— | −9.0—−146080% | −4.6—−1316% | −1.8—−348% | |
| Interest expense and finance costs | — | — | — | — | — | — | — | 0−100%0.0% | 0.0−40.8%12.1% | 0.1—14.0% | |
| Other non-operating income (expense) | −1.3—— | −0.7−250%— | 0.5—— | −0.0−108%— | 0.3—— | −0.2—— | −2.5—— | −0.8—−12589% | −0.8—−214% | — | |
| Income before tax | −7.0—— | −12—— | −10—— | −13—— | −11—— | −12—— | −13—— | −9.8—−158670% | −5.4—−1529% | −2.8—−538% | |
| Income tax | — | 0—— | 0—— | 0—— | 0—— | 0—— | 0—— | 0—0.0% | 0—0.0% | 0—0.0% | |
| Net income including minority interests | — | −12—— | −10−176%— | 13+17.3%— | 11−4.2%— | 12r−12—— | −13—— | −9.8—−158670% | −5.4—−1529% | −2.8—−538% | |
| Net income attributable to shareholders | −7.0—— | −12—— | −10—— | −13—— | −11—— | −12—— | −13—— | −9.8—−158670% | −5.4—−1529% | −2.8—−538% | |
| Earnings per share, basic | -8.93—— | -56.94—— | — | -4.56—— | -5.55r-0.28—— | -0.63—— | -2.34—— | -2.17—— | -1.95—— | -3.84—— | |
| Earnings per share, diluted | -8.93—— | -56.94—— | -2,766.85—— | — | — | -0.63—— | -2.34—— | -2.17—— | -1.95—— | -3.84—— | |
| Shares, weighted average (basic) | 0.8+289%— | 0.2—— | — | — | — | — | — | — | — | — | |
| Shares, weighted average (diluted) | 0.8+289%— | 0.2+5458%— | 0.0—— | — | — | 19+156%— | 7.5+66.5%— | 4.5+63.4%— | 2.8+281%— | 0.7—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 0.8−76.4%19.8% | 3.2+14.0%72.5% | 2.8−42.0%42.0% | 4.9−48.3%52.7% | 9.5+30.9%73.5% | 7.2+17.1%82.5% | 6.2−4.6%86.0% | 6.5+15.5%89.6% | 5.6+3765%91.5% | 0.1—29.5% | |
| Receivables | — | — | — | — | — | — | — | 0−100%0.0% | 0.0—0.1% | 0—0.0% | |
| Inventory | 0—0.0% | 0−100%0.0% | 2.6−0.8%38.8% | 2.6+106%28.5% | 1.3+118%10.0% | 0.6+420%6.7% | 0.1+90.8%1.6% | 0.1−69.0%0.8% | 0.2+378%3.1% | 0.0—8.2% | |
| Other current assets | — | — | — | — | — | 0.0−95.4%0.1% | 0.1−52.2%1.8% | 0.3+1818%3.8% | 0.0+35.3%0.2% | 0.0—2.1% | |
| Current assets | 1.0−71.8%25.1% | 3.4+13.2%77.1% | 3.0−43.6%44.9% | 5.4r8.5−55.5%58.0% | 12+47.4%93.9% | 8.2r8.2+25.6%93.6% | 6.5−6.0%91.1% | 6.9+18.1%96.2% | 5.9r5.9+2907%96.1% | 0.2r0.2—39.9% | |
| Property, plant and equipment | 0.0−38.6%1.1% | 0.1−38.0%1.6% | 0.1−52.6%1.7% | 0.2+79.7%2.5% | 0.1−38.2%1.0% | 0.2−10.2%2.4% | 0.2−13.5%3.3% | 0.3+13.1%3.8% | 0.2−18.2%3.9% | 0.3—60.1% | |
| Right-of-use (leased) assets | 0.5−20.1%12.0% | 0.6+63.2%13.0% | 0.4−30.0%5.2% | 0.5−21.4%5.5% | 0.6+89.8%5.0% | 0.3−16.3%3.9% | 0.4—5.6% | 0—0.0% | — | — | |
| Total assets | 3.9−13.4%100% | 4.5−34.1%100% | 6.8−27.2%100% | 9.3−28.0%100% | 13+46.9%100% | 8.8+22.1%100% | 7.2−0.6%100% | 7.2+17.9%100% | 6.1r6.1+1148%100% | 0.5—100% | |
| Accounts payable | 0.4+42.0%9.9% | 0.3−25.2%6.1% | 0.4−41.3%5.3% | 0.6−22.4%6.6% | 0.8+96.3%6.1% | 0.4−68.5%4.6% | 1.3+102%17.8% | 0.6−19.1%8.7% | 0.8r0.8+243%12.7% | 0.2—46.4% | |
| Current liabilities | 0.8+24.1%19.5% | 0.6−33.0%13.6% | 0.9−47.0%13.4% | 1.7+10.4%18.4% | 1.5+56.5%12.0% | 1.0−52.4%11.3% | 2.1+113%28.9% | 1.0+14.9%13.5% | 0.8r0.8−38.7%13.9% | 1.4—282% | |
| Lease liabilities (non-current) | 0.4−25.5%9.4% | 0.5+154%10.9% | 0.2−47.5%2.8% | 0.4−29.4%3.9% | 0.5+90.6%4.0% | 0.3−20.7%3.1% | 0.3—4.8% | 0—0.0% | — | — | |
| Non-current liabilities | 0.8−34.5%21.9% | 1.3+570%28.9% | 0.2−47.5%2.8% | 0.4—3.9% | — | 0.6+77.6%6.9% | 0.3—4.8% | 0—0.0% | — | — | |
| Total liabilities | 1.6−15.8%41.4% | 1.9+72.8%42.5% | 1.1−47.1%16.2% | 2.1−1.0%22.3% | 2.1+31.0%16.2% | 1.6−33.9%18.2% | 2.4+148%33.7% | 1.0+14.9%13.5% | 0.8r0.8−38.7%13.9% | 1.4—282% | |
| Retained earnings | −110—−2866% | −103—−2323% | −92—−1361% | −82—−883% | −69—−534% | −57—−654% | −45—−630% | −28—−383% | −18—−292% | −13—−2551% | |
| Shareholders' equity | 2.3−11.7%58.6% | 2.6−54.8%57.5% | 5.7−21.5%83.8% | 7.2−33.2%77.7% | 11+50.4%83.8% | 7.2r7.2+50.6%81.8% | 4.8−23.8%66.3% | 6.2+18.4%86.5% | 5.3—86.1% | −0.9—−182% | |
| Total liabilities and equity | 3.9−13.4%100% | 4.5−34.1%100% | 6.8−27.2%100% | 9.3−28.0%100% | 13+46.9%100% | 8.8+22.1%100% | 7.2−0.6%100% | 7.2+17.9%100% | 6.1r6.1+1148%100% | 0.5—100% | |
| Shares outstanding | 1.2+119%— | 0.5+8943%— | 0.0r10−99.8%— | 3.2+48.9%— | 2.1r43−93.8%— | 34+304%— | 8.4+13.5%— | 7.4+89.2%— | 3.9+442%— | 0.7—— | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | 0.0−5.3%— | 0.0−62.4%— | 0.1+28.0%— | 0.1−16.8%— | 0.1+17.0%— | 0.1+23.3%— | 0.1+17.9%— | 0.1+11.1%1107% | 0.1−5.3%17.5% | 0.1—12.6% | |
| Share-based compensation | 0.3−42.4%— | 0.6−42.6%— | 1.0−17.0%— | 1.2−16.9%— | 1.4−31.3%— | 2.1—— | — | — | — | — | |
| Cash from operating activities | −5.2—— | −7.4—— | −9.5—— | −13—— | −11—— | −11—— | −8.6—— | −7.7—−124757% | −3.3r−3.3—−939% | −1.3—−255% | |
| Capital expenditure | −0.0—— | −0.0—— | −0.0—— | −0.2—— | −0.0—— | −0.1—— | −0.0—— | −0.1—−1620% | −0.0—−2.2% | — | |
| Intangible assets bought | −3.0—— | — | — | — | — | — | — | — | — | — | |
| Cash from investing activities | −3.0—— | −0.0—— | −0.0—— | −0.2—— | −0.0—— | −0.1—— | −0.0—— | −0.1—−1620% | −0.0—−2.2% | 0—0.0% | |
| Debt repaid | — | −0.0—— | — | — | — | — | — | — | — | — | |
| Shares issued | 1.2−77.3%— | 5.4r1.1−17.2%— | 6.5−22.8%— | 8.4−20.9%— | 11+56.6%— | 6.8+5325%— | 0.1−98.4%— | 7.7−9.9%125311% | 8.6+171714%2443% | 0.0—1.0% | |
| Cash from financing activities | 5.7−26.6%— | 7.8+3.9%— | 7.5−10.5%— | 8.4−37.3%— | 13+12.9%— | 12+42.5%— | 8.3−3.9%— | 8.7−1.1%140460% | 8.8+508%2493% | 1.4—280% | |
| Report | 10-K | 10-K | 10-K/A | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Jun 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 | Q3 FY2023to Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Research and development | 2.0−16.7%— | 0.2−38.7%— | 0.8+46.9%— | 0.5*−20.3%— | 0.4−45.6%— | 0.4−46.8%— | 0.5−49.2%— | 0.6*+10.1%— | 0.8−51.3%— | 0.7—— | 1.0—— | 0.6*—— | 1.6—— | |
| Selling and marketing | 0.1−79.9%— | 0.0−91.6%— | 0.0−93.8%— | 0.0*−92.6%— | 0.0−45.5%— | 0.1−57.8%— | 0.1−71.1%— | 0.1*−41.6%— | 0.1−65.8%— | 0.2—— | 0.2—— | 0.1*—— | 0.2—— | |
| General and administrative | 4.6−21.7%— | 1.2+46.1%— | 1.4+59.8%— | 1.1*−69.0%— | 0.9+41.5%— | 0.9−37.0%— | 0.9−41.9%— | 3.6*+389%— | 0.6−49.6%— | 1.4—— | 1.5—— | 0.7*—— | 1.3—— | |
| Operating expenses | 6.6−22.5%— | 1.5+14.0%— | 2.2+47.9%— | 1.6*−62.2%— | 1.4−9.2%— | 1.3−41.7%— | 1.5−47.2%— | 4.3*+195%— | 1.5−51.8%— | 2.2—— | 2.8—— | 1.5*—— | 3.1—— | |
| Operating income | −6.6—— | −1.5—— | −2.2—— | −1.6*—— | −1.4—— | −1.3—— | −1.5—— | −4.3*—— | −1.5—— | −2.2—— | −2.8—— | −1.5*—— | −3.1—— | |
| Other non-operating income (expense) | 0.7—— | 1.6+2086%— | 0.9+99.2%— | −1.5*−1147%— | −0.2—— | 0.1r0.0+4322%— | 0.4r0.0+8843%— | 0.1*—— | −0.8−3094%— | 0.0—— | 0.0r−0.0—— | −0.0*—— | 0.0—— | |
| Income before tax | −5.9—— | 0.2—— | −1.3—— | −3.2*—— | −1.6—— | −1.2—— | −1.0—— | −4.1*—— | −2.4—— | −2.2—— | −2.8—— | −1.5*—— | −3.1—— | |
| Income tax | — | — | — | — | — | 0—— | 0—— | 0*—— | 0—— | 0—— | 0—— | 0*—— | 0—— | |
| Net income including minority interests | — | 0.2—— | — | — | — | −1.2—— | −1.0—— | −19*—— | 12*−12.3%— | −2.2r−7.8*—— | −2.8r2.8—— | −19*—— | 14r−3.1*—— | |
| Net income attributable to shareholders | −5.9—— | 0.2—— | −1.3—— | −3.2*—— | −1.6—— | −1.2—— | −1.0—— | −4.1*—— | −2.4—— | −2.2—— | −2.8—— | −1.5*—— | −3.1—— | |
| Earnings per share, basic | — | 0.12—— | -1.09—— | — | -2.10—— | -1.71—— | -1.86—— | — | -9.54—— | — | — | — | — | |
| Earnings per share, diluted | — | 0.06—— | -1.09—— | — | -2.10—— | -1.71—— | -1.86—— | — | -9.54—— | — | — | — | — | |
| Shares, weighted average (basic) | 1.3+84.6%— | 1.3+84.6%— | 1.2+115%— | — | 0.8+208%— | 0.7—— | 0.6—— | — | 0.2—— | — | — | — | — | |
| Shares, weighted average (diluted) | 2.5+245%— | 2.5+245%— | 1.2+115%— | — | 0.8+208%— | 0.7—— | 0.6—— | — | 0.2—— | — | — | — | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 1.7—21.9% | 1.7−3.8%21.9% | 0.4−82.7%10.4% | 0.8−76.4%19.8% | 0.8−83.3%40.4% | 1.8−71.7%64.4% | 2.1+82.0%65.1% | 3.2+14.0%72.5% | 4.7+42.3%56.6% | 6.4—61.3% | 1.1—22.4% | 2.8—42.0% | 3.3—43.9% | |
| Inventory | — | — | — | 0—0.0% | 0−100%0.0% | 0−100%0.0% | 0−100%0.0% | 0−100%0.0% | 2.7−1.7%32.4% | 2.7—26.0% | 2.7—53.6% | 2.6—38.8% | 2.8—36.3% | |
| Current assets | 5.6—70.3% | 5.6+202%70.3% | 0.5−75.4%15.6% | 1.0−71.8%25.1% | 1.0−78.9%53.4% | 1.9−72.4%66.0% | 2.2+71.6%68.8% | 3.4+13.2%77.1% | 5.0−22.4%59.2% | 6.7—64.3% | 1.3—25.1% | 3.0—44.9% | 6.4—84.2% | |
| Property, plant and equipment | 0.0—0.5% | 0.0−31.3%0.5% | 0.0−47.9%1.0% | 0.0−38.6%1.1% | 0.1−34.4%2.7% | 0.1−30.9%2.3% | 0.1r0.1−43.1%2.0% | 0.1−38.0%1.6% | 0.1−50.1%1.0% | 0.1—0.9% | 0.1—2.2% | 0.1—1.7% | 0.2—2.1% | |
| Right-of-use (leased) assets | 0.4—5.0% | 0.4−22.9%5.0% | 0.4−21.0%12.6% | 0.5−20.1%12.0% | 0.5+114%25.0% | 0.5+91.0%18.5% | 0.5+74.1%17.2% | 0.6+63.2%13.0% | 0.2−41.6%2.7% | 0.3—2.6% | 0.3—6.2% | 0.4—5.2% | 0.4—5.2% | |
| Total assets | 7.9—100% | 7.9+183%100% | 3.4+8.4%100% | 3.9−13.4%100% | 2.0−76.6%100% | 2.8−73.1%100% | 3.2−37.3%100% | 4.5−34.1%100% | 8.4+10.2%100% | 10—100% | 5.1—100% | 6.8—100% | 7.6—100% | |
| Accounts payable | 0.5—5.9% | 0.5+64.9%5.9% | 0.5+104%13.3% | 0.4+42.0%9.9% | 0.3−9.6%12.9% | 0.3−6.1%10.0% | 0.2−57.1%7.1% | 0.3−25.2%6.1% | 0.3−33.3%3.3% | 0.3—2.9% | 0.5—10.3% | 0.4—5.3% | 0.4—5.5% | |
| Current liabilities | 0.8—9.9% | 0.8+36.4%9.9% | 0.8+47.7%24.3% | 0.8+24.1%19.5% | 0.8−1.7%40.7% | 0.6−57.3%20.5% | 0.6−53.5%17.8% | 0.6−33.0%13.6% | 0.8−62.5%9.7% | 1.4—12.9% | 1.2—24.0% | 0.9—13.4% | 2.2—28.5% | |
| Lease liabilities (non-current) | 0.3—3.7% | 0.3−32.3%3.7% | 0.3−29.0%9.5% | 0.4−25.5%9.4% | 0.4+696%20.2% | 0.4+336%15.3% | 0.5+216%14.5% | 0.5+154%10.9% | 0.0−79.0%0.6% | 0.1—0.9% | 0.1—2.9% | 0.2—2.8% | 0.2—3.1% | |
| Non-current liabilities | 0.8—10.7% | 0.8+11.6%10.7% | 0.8−4.2%23.7% | 0.8−34.5%21.9% | 1.0+3.3%50.5% | 0.8+670%27.0% | 0.9+484%26.9% | 1.3+570%28.9% | 1.0+305%11.5% | 0.1—0.9% | 0.1—2.9% | 0.2—2.8% | 0.2—3.1% | |
| Total liabilities | 1.6—20.6% | 1.6+22.3%20.6% | 1.7+16.5%48.0% | 1.6−15.8%41.4% | 1.8+1.0%91.3% | 1.3−7.9%47.5% | 1.4+4.1%44.7% | 1.9+72.8%42.5% | 1.8−26.3%21.2% | 1.4—13.9% | 1.4—26.9% | 1.1—16.2% | 2.4—31.7% | |
| Retained earnings | −112—−1405% | −112—−1405% | −112—−3251% | −110—−2866% | −107—−5463% | −106—−3765% | −104—−3295% | −103—−2323% | −99—−1185% | −97—−928% | −95—−1871% | −92—−1361% | −90—−1190% | |
| Shareholders' equity | 6.3—79.4% | 6.3+328%79.4% | 1.8+1.9%52.0% | 2.3−11.7%58.6% | 0.2−97.4%8.7% | 1.5−83.6%52.5% | 1.8−52.6%55.3% | 2.6−54.8%57.5% | 6.6+27.1%78.8% | 9.0—86.1% | 3.7—73.1% | 5.7—83.8% | 5.2—68.3% | |
| Total liabilities and equity | 7.9—100% | 7.9+183%100% | 3.4+8.4%100% | 3.9−13.4%100% | 2.0−76.6%100% | 2.8−73.1%100% | 3.2−37.3%100% | 4.5−34.1%100% | 8.4+10.2%100% | 10—100% | 5.1—100% | 6.8—100% | 7.6—100% | |
| Shares outstanding | 1.5—— | 1.5+99.3%— | 1.2+121%— | 1.2+119%— | 0.8+47.1%— | 0.8−99.0%— | 0.6−94.8%— | 0.5+8943%— | 0.5−93.6%— | 72—— | 11—— | 0.0r10—— | 8.4—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | 0.0−15.5%— | 0.0*−12.8%— | 0.0−31.1%— | 0.0*−8.0%— | 0.0*−6.2%— | 0.0*+7.6%— | 0.0−9.9%— | 0.0*−49.7%— | 0.0*−64.1%— | 0.0*—— | 0.0—— | 0.0*—— | 0.0*—— | |
| Share-based compensation | 1.3—— | 0.5*+1271%— | 0.6+592%— | 0.0*−87.7%— | 0.1*—— | 0.0−78.8%— | 0.1−73.8%— | 0.1*−58.2%— | — | 0.2*—— | 0.3—— | 0.3*—— | 0.3*—— | |
| Cash from operating activities | −4.8—— | −0.9*—— | −1.1—— | −1.6*—— | −1.2*—— | −1.1*—— | −1.3—— | −1.5*—— | −1.7*—— | −2.1*—— | −2.1—— | −2.2*—— | −2.6*—— | |
| Capital expenditure | — | — | — | 0*—— | 0*—— | 0*—— | −0.0—— | 0*—— | 0*—— | — | −0.0—— | −0.0*—— | 0*—— | |
| Cash from investing activities | −0.3—— | 2.2*—— | 0.5—— | −3.0*—— | 0*—— | 0*−100%— | −0.0—— | 0*−100%— | 0*—— | 0.0*—— | −0.0—— | 0.0*—— | 0*—— | |
| Debt repaid | — | — | — | — | — | 0*—— | 0—— | — | 0*—— | 0*—— | −0.0—— | — | — | |
| Shares issued | 0.6−89.0%— | 0.1*−89.0%— | 0.3+80.9%— | 0.1*−98.4%— | 0.1*—— | 0.9*+17.7%— | 0.1−65.3%— | 4.2r0*+542%— | 0*−100%— | 0.7*—— | 0.4—— | 0.7*—— | 1.1*—— | |
| Cash from financing activities | 8.9+784%— | 3.9*+354%— | 0.3+80.9%— | 4.6*—— | 0.1*+8781%— | 0.9*−88.3%— | 0.1−68.9%— | 0*−100%— | 0.0*−99.8%— | 7.3*—— | 0.5—— | 1.7*—— | 1.1*—— | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K/A | 10-Q | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Jun 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Executive pay at Endra Life Sciences Inc.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2024Alexander Tokman | $215 K | $195 K | $148 K | $30 |
Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2024
Events at Endra Life Sciences Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Delisting notice 2 · Restructuring 1 · Change in control 1 · Directors and officers 2 · Material agreement 5 · Agreement ended 1 · Unregistered share sale 2 · Shareholder rights changed 1 · Bylaws or fiscal year changed 2 · Shareholder vote 1 · Results announced 6
| Filed | What happened | Filing |
|---|---|---|
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Change in controlMaterial agreement | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Delisting notice | 8-K | |
| Results announced | 8-K | |
| Restructuring | 8-K | |
| Directors and officersBylaws or fiscal year changedShareholder vote | 8-K | |
| Directors and officers | 8-K | |
| Material agreement | 8-K | |
| Material agreementAgreement endedUnregistered share sale | 8-K/A | |
| Results announced | 8-K | |
| Delisting notice | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Shareholder rights changedBylaws or fiscal year changed | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Oct 1, 2026
Acquisitions and funding#
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Oct 2025 | $14 M | Private placement after listing | $10 to $50 million | 6 | equity | SEC |
| Dec 2019 | $9 M | Private placement after listing | $2 to $10 million | 151 | equity, debt | SEC |
| Jul 2019 | $3 M | Private placement after listing | $2 to $10 million | 86 | debt, options | SEC |
| Jun 2018 | $1 M | Private placement after listing | Under $2 million | 18 | equity, debt | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
From US state WARN notices and SEC 8-K restructuring filings, newest first.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | · | · | · | · | · | · | · | · | · | · | · | — |
| Announced | People | Kind | Where | Source |
|---|---|---|---|---|
| Not stated | Restructuring planSEC 8-K | Company-wide plan | Filing |
Source: State WARN notices and SEC 8-K item 2.05
How Endra Life Sciences Inc. compares in Diagnostics and Research
- Market cap$7 M · higher than 10% of 110
- Revenue growth-97.1% · higher than 0% of 89
- Price / book3.3× · lower than 45% of 84
- FCF yield-70.2% · higher than 8% of 66
Peer comparison · Diagnostics and Research
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Endra Life Sciences Inc.🇺🇸 | $7 M | — | — | -97.1% |
| Thermo Fisher Scientific Inc.🇺🇸 | $253.8 B | 35.9× | 14.9% | +3.9% |
| Danaher Corporation🇺🇸 | $166.7 B | 38.5× | 16.9% | +2.9% |
| WuXi AppTec Co., Ltd.🇨🇳 | $70.4 B | 25.4× | 42.1% | — |
| Natera, Inc.🇺🇸 | $58.7 B | — | -5.7% | +35.9% |
| Siemens Healthineers AG🇩🇪 | $52.8 B | 22.9× | 8.7% | — |
| Lonza Group AG🇨🇭 | $51.9 B | — | -4.2% | — |
| Agilent Technologies, Inc.🇺🇸 | $48.8 B | 33.9× | 19.5% | +6.7% |
| IQVIA Holdings Inc.🇺🇸 | $45.1 B | 32.4× | 8.1% | +5.9% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
Sources and freshness
- Market cap:
- Oct 30, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As of December 31, 2025
- Profile updated:
- Nov 18, 2026
Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Endra Life Sciences Inc.? Verify and update this profile — free
Show Endra Life Sciences Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.